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Abstract
Introduction and hypothesis The objective of this study was
to compare the functional outcomes after pessary treatment
and after prolapse surgery as primary treatments for pelvic
organ prolapse (POP).
Methods This was a prospective cohort study performed in a
Dutch teaching hospital in women with symptomatic POP of
stage II or higher requiring treatment. Patients were treated
according to their preference with a pessary or prolapse sur-
gery. The primary endpoint was disease-specific quality of life
at 12 months follow-up according to the prolapse domain of
the Urogenital Distress Inventory (UDI) questionnaire.
Secondary outcomes included adverse events and additional
interventions. To show a difference of ten points in the prima-
ry outcome, we needed to randomize 80 women (power 80%,
α 0.05, taking 10% attrition into account).
Results We included 113 women (74 in the pessary group, 39
in the surgery group). After 12 months, the median prolapse
domain score was 0 (10th to 90th percentile 0–33) in the
pessary group and 0 (10th to 90th percentile 0–0) in the sur-
gery group (p < 0.01). Differences in other domain scores
were not statistically significant. In the pessary group, 28%
(21/74) of the women had a surgical intervention versus 3%
(1/39) reoperations in the surgery group (p = 0.01).
Conclusions In women with POP of stage II or higher under-
going surgery, prolapse symptoms were less severe than in
those who were treated with a pessary, but 72% of women
who were treated with a pessary did not opt for surgery.
Trial registration number: Dutch trial register NTR2856.
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Introduction
Pelvic organ prolapse (POP) is a common condition. In a
general Dutch female population aged 45–85 years, 75% of
women had some degree of POP [1, 2]. Around 10% of wom-
en undergo surgery at some time in their lives for the manage-
ment of prolapse or urinary incontinence [2]. Pessaries have
been used as conservative treatment since the beginning of
recorded history. Pessaries are used for the treatment of POP
by more than 85% of gynaecologists and 98% of
urogynaecologists [3, 4]. Patient preference plays a very im-
portant role in the willingness to try a pessary according to a
Dutch study showing that 48% of treatment-naive women
prefer surgery, 36% prefer pessary treatment and 16% have
no preference [5]. However, relevant cost savings can be re-
alized as pessary therapy is inexpensive and the costs are
mainly related to doctor visits and the treatment of side effects,
which would be even lower in self-managing patients (van de
Waarsenburg and van de Vaart, unpublished, 2014. Pessary or
surgery for symptomatic organ prolapse: study protocol,
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version 1.4). Although pessaries have been reported to be
effective in reducing prolapse symptoms [6–11], 20–50% of
women discontinue pessary use within 1 year [12, 13]. Side
effects have been reported to occur in half of the women and
are the main reason for discontinuation [12].
The aim of POP surgery is to reduce bother related to pelvic
floor symptoms by restoring the anatomy of the vagina and
surrounding visceral organs. Unfortunately, POP surgery can
be associated with complications. Furthermore, there are sig-
nificant cost implications for prolapse surgery, particularly
when the index surgery has a quoted failure rate of up to
30% [11]. According to two prospective trials comparing pes-
sary treatment with POP surgery, women treated with pessary
and women treated with surgery report similar improvements
in urinary and bowel symptoms, sexual function, and quality
of life [11, 14]. There are no randomized controlled trials
(RCT) comparing pessary treatment and surgery. Although
POP surgery has several advantages over pessary treatment,
the risk of complications is higher and it might be less cost-
effective. Since previous studies have shown promising re-
sults with pessary treatment, it might be an equivalent option
in the treatment of POP, probably with less risk and lower cost.
In view of this dilemma, we decided to start a study with a
prospective cohort group treated with either pessary or POP
surgery to individualize counselling on treatment options and
to guide patients better in the treatment decision process. The
aim of this study was to compare disease-specific quality of
life after 12 months between pessary treatment and surgery in
women treated for POP. In this superiority study, we assumed
that POP surgery would lead to a higher disease-specific qual-
ity of life than pessary treatment at 12 months after the start of
treatment.
Materials and methods
We performed this RCT comparing pessary treatment and
prolapse surgery as primary treatments for POP in a teaching
hospital in The Netherlands. The study was approved by the
ethics committee and is registered with the Dutch trial register
(NTR2856). Women with a treatment preference who did not
consent to randomization were asked to follow the same study
protocol as part of a prospective cohort group. During the
study, many women were found to have a strong preference
for one or other of the treatment options, and did not consent
to randomization. Therefore, the RCTwas prematurely ended,
resulting in a prospective cohort group, including 6 random-
ized women and 107 women treated according to their
preference.
Women with symptomatic POP who preferred to undergo
treatment were eligible for the trial. Symptomatic POP was
defined as Pelvic Organ Prolapse Quantification (POP-Q)
stage II or higher with bothersome urogenital symptoms.
Women who had undergone previous surgery for correction
of POP or urinary incontinence, or who had previously been
treated with a pessary were excluded, as were patients with a
contraindication to surgical intervention. An isolated rectocele
without prolapse of any other compartment was also an exclu-
sion criteria, since if a solitary rectocele is present there may
be insufficient support for a pessary [11].
Eligible women with symptomatic POP who met the inclu-
sion criteria were counselled about POP and their condition by
their own gynaecologist , one of a team of three
urogynaecologists. Then the treatment options expectant man-
agement, pessary treatment and surgery were explained. After
the consultation, women received written information about
their condition and about the trial. They then had time to
consider participation in the trial, being randomized or being
part of the prospective cohort group. The interventions were
either pessary treatment or POP surgery following patient
preference. If the patient consented to randomization she
signed written informed consent and was randomized.
Randomization was performed using opaque sealed enve-
lopes. The treatment allocation ratio was 1:1 to either pessary
treatment or surgery. No block randomization was performed.
Patients and physicians were not blinded.
Pessary treatment
According to the judgement of the gynaecologist, either a
shelf (Falk) or a ring pessary (with or without central support)
could be used. No other pessaries were placed during the trial.
Preferably a ring pessary was placed. According to the judge-
ment of the physician, a ring pessary with central support was
placed in patients with apical descent, and a shelf (Falk) pes-
sary was placed in patients with apical descent, extensive pro-
lapse or lack of support of the ring pessary. Pessary fitting was
performed at the outpatient clinic after fitting. A test pessary
was used to determine the correct size of the pessary. The
patient tested this pessary while walking around for 30 min.
If the right size was found, the pessary was inserted and the
fitting was considered successful. The type and size of pessary
were recorded, as well as the number of different types and
sizes. Side effects during pessary treatment including dis-
charge, pain and blood loss were also recorded. After place-
ment, all patients received instructions about pessary treat-
ment. If the initial fit was unsuccessful another size or the
other pessary type could be used, according to the judgement
of the gynaecologist. Discontinuation and expulsion were re-
corded, and if pessary treatment was not successful, the reason
for failure was also recorded.
A follow-up visit 6 weeks after placement was planned,
and patients were instructed to return to the clinic if they had
any complaints or if they lost the pessary. If the patients was
satisfied with the pessary, follow-up visits every 3–4 months
were planned for pessary cleaning and vaginal inspection.
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During the follow-up period, the type or size of the pessary
could be changed. All participating physicians were skilled in
pessary fitting and had performed at least 100 pessary fittings
prior to the start of the trial.
Surgical intervention
The surgical intervention consisted of correction of all com-
partments that required surgery. The decisions as to which
technique to use and which compartments to treat were left
to the discretion of the gynaecologist, and depended on the
results of the physical examination and the complaints.
Cystocele repair involved conventional anterior colporrhaphy.
For uterine descent, different techniques were allowed. These
techniques could be vaginal hysterectomy with vault suspen-
sion or uterus-preserving techniques such as sacrospinous fix-
ation, the Manchester-Fothergill procedure or a laparoscopic
sacrohysteropexy. A coexisting rectocele was treated with
conventional posterior colporrhaphy. When stress inconti-
nence was diagnosed prior to surgery, the patient and surgeon
decided whether to perform a concomitant incontinence pro-
cedure or whether first to perform prolapse surgery only with
additional incontinence surgery later.
All procedures were performed under general anaesthesia
or spinal anaesthesia. Prophylactic antibiotics were given
peroperatively (metronidazole/cefalozine). As prophylaxis
for thromboembolism, low molecular weight heparin was ad-
ministered subcutaneously peroperatively and postoperative-
ly. The data collected included the type of surgery, procedure
time, estimated blood loss, length of hospital stay and periop-
erative complications. A urethral catheter was left in situ and
was removed on the second postoperative day in women with
anterior colporrhaphy or on the first day in other patients. If
the procedure was complicated by a bladder lesion, the cath-
eter was removed after 1 week. If urine retention occurred
after removal of the catheter on the first day, the catheter
was reinserted for another day.
Women were asked to complete a questionnaire before sur-
gery, and at 3–6 months and 12 months after treatment. All
patients were asked to undergo a pelvic examination before
treatment, at 6 weeks after treatment and when clinically in-
dicated. Pelvic examination after 1 year was performed in
women who were still followed up by their physician.
Randomized patients were invited for examination after
12 months. During pelvic examinations, POP-Q stage was
determined [15] in the lithotomy position and during a
Valsalva manoeuvre. Other findings of the pelvic examination
including vaginal erosion, vaginal discharge, atrophy, bleed-
ing and urinary incontinence were also recorded.
The primary outcome of the studywas the functional outcome
evaluated using the Urogenital Distress Inventory (UDI) [16]
after 12 months. The UDI is a questionnaire that has been vali-
dated in Dutch for evaluating prolapse-related symptoms. The
UDI is a disease-specific questionnaire comprising 17 questions
for assessing the presence and experienced discomfort of pelvic
floor problems. The UDI consists of five domains: discomfort/
pain, urinary incontinence, overactive bladder, genital prolapse,
and obstructive micturition. The UDI scores were calculated for
al five domains [16]. The questionnaire also includes versions of
the Defecatory Distress Inventory (DDI) [17] and the
Incontinence Impact Questionnaire (IIQ) [16]. The question-
naires also include questions about sexual function. If partici-
pants did not respond they were sent the questionnaire a second
time. If they ignored both questionnaires, they were contacted
by telephone to find the reason.
Additional interventions could include physiotherapy and
incontinence surgery in the pessary group, and physiotherapy,
incontinence surgery or surgery for recurrent prolapse in the
surgery group. Long-term complications and side effects were
recorded in both groups. The remaining study parameters in-
cluded age, body mass index, parity, menopausal status, pres-
ence of incontinence and use of oestrogens. Urinary stress
incontinence was diagnosed with the patient in the lithotomy
position with a full bladder. The patient was asked to cough
several times. If urinary leakage was seen, urinary inconti-
nence was diagnosed. In patients with a cystocele, the
cystocele was redressed and the examination was repeated.
Sample size
Disease-specific quality of life as evaluated using the UDI
questionnaire was the primary endpoint. A difference between
the two interventions of ten points in the prolapse domain of
the UDI 12 months after treatment was considered clinically
relevant [18]. Assuming a standard deviation of the score in
this domain of 15 points, 72 patients were needed to show a
statistically significant difference in the primary outcome
(power of 80%, α error 0.05) [18]. Taking into account a
10% attrition rate, 80 patients (40 in each arm) needed to be
included. After the RCTwas halted, we focused on the cohort
group which was part of the trial, since randomization turned
out to be very difficult. We included patients until there were
at least 40 patients in both groups.
Statistical analysis
The aim of the trial was to determine whether surgery was
superior to pessary treatment in terms of the primary endpoint
(prolapse domain of the UDI). For both nonrandomized and
randomized groups, data were analysed according to the
intention-to-treat principle. The domain scores were calculat-
ed for UDI, DDI and IIQ at baseline and after 12 months in
both groups. The scores for these domains vary between zero
and 100. A high score in a particular domain indicates more
bothersome symptoms or worse quality of life. To examine
differences between groups we used an unpaired t test or the
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Mann-Whitney test for continuous variables, depending on
the distribution, and the chi-squared test was used for dichot-
omous variables. The Wilcoxon signed-ranks test was used to
compare the domain scores before and after treatment in both
groups separately. Two-sided significance tests were used, and
p values <0.05 were considered to indicate statistical signifi-
cance. For dichotomous outcomes, relative risks and 95%
confidence intervals were calculated. All analyses were done
with IBM SPSS statistics 22 (IBM, Armonk, NY).
Results
Between June 2009 and July 2014, 113 women were invited to
participate in the study, of whom six gave informed consent for
randomization, and 107 women expressed a treatment prefer-
ence and participated in the prospective cohort study (72 pre-
ferred pessary treatment and 35 preferred prolapse surgery).
The remaining six gave informed consent for randomization
(two in the pessary group and four in the surgery group). As
a result of the slow recruitment, we decided to halt the trial on
30 June 2014, leaving six women randomized and 107 women
treated according to their preference.We performed an integrat-
ed analysis for randomized and nonrandomized patients,
resulting in 74 women initially treated with pessary and 39
initially treated surgically (Fig. 1).
Table 1 shows the baseline characteristics of the study pop-
ulation. The pessary group was significantly older than the
surgery group. Also, women in the pessary group had higher
POP-Q stages of the anterior (p < 0.001) and posterior
(p = 0.02) compartments than the surgery group. The surgery
group did not include patients with POP-Q stage IV.
Table 2 shows domain scores for the UDI, DDI, IIQ and
sexual behaviour before treatment at baseline and after
12 months in both groups. The baseline overactive bladder
scores were 11 (10th to 90th percentile 0–44) in the pessary
group and 22 (10th to 90th percentile 0–58) in the surgery
group (p = 0.02). The baseline pain/discomfort domain scores
were 16 (10th to 90th percentile 0–63) in the pessary group
and 33 (10th to 90th percentile 0–70) in the surgery group
(p < 0.01). The baseline social impact of incontinence domain
scores were 0 (10th to 90th percentile 0–22) in the pessary
group and 11 (10th to 90th percentile 0–44) in the surgery
group (p < 0.01).
The UDI prolapse domain score at 12 months was the
primary outcome (Table 2). After 12 months, the median pro-
lapse domain scores were 0 (10th to 90th percentile 0–33) in
the pessary group and 0 (10th to 90th percentile 0–0) in the
surgery group (p < 0.01), meaning that in the pessary group,
10% of the patients had a score of 33 or more in the domain
Bgenital prolapse^, compared to all patients in the surgery
group with a score of 0 in this domain. Other domain scores
were not significantly different. The UDI prolapse domain
Studied (n=113)
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Fig. 1 Patient flow chart
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scores had improved significantly in both groups at 12months
after treatment (p < 0.01).
Data concerning the initial treatment in the pessary group
and the surgery group are presented in Tables 3 and 4, respec-
tively. A ring pessary was used in most women in the pessary
group (N = 64, 87%), followed by a shelf (Falk) pessary
(N = 10, 14%). No other types of pessary were used during
the follow-up period. There were no patients in the pessary
group in whom we could not find a pessary that fitted at the
first visit. Anterior colporrhaphy was the intervention per-
formed in most women (74%) in the surgery group. Other
techniques performed were laparoscopic hysteropexy (N = 1,
3%), sacrospinous fixation (N = 10, 26%), posterior
colporrhaphy (N = 10, 26%), the Manchester-Fothergill pro-
cedure (N = 2, 5%), and transvaginal hysterectomy (N = 3,
8%).
In the pessary group (Table 3), 49% of patients (36/74) had
a side effect. The most common side effects were vaginal
discharge (20%) and vaginal pain (14%). No urinary tract
infections or vaginal ulcers were reported. During the
follow-up period, 36% of patients (27/74switched to another
type or size of pessary. Pessary expulsion occurred in 14% of
patients (10/74). The continuation rate at 12 months was 60%.
The reasons for discontinuation were expulsion, urinary
Table 1 Baseline characteristics
of the study population Characteristic Group p-value
Pessary (N = 74) Surgery (N = 39)
Age (years), mean (range) 63.2 (60.4–65.9) 57.6 (53.8–61.4) 0.02
Body mass index (kg/m2), median (IQR) 25.8 (25.0–26.6) 24.6 (23.5–25.7) 0.07
Parity, n/N (%)
0 0/74 (0) 0/39 (0) 0.84
1 9/74 (12) 4/39 (10)
2 35/74 (47) 22/39 (56)
3 19/74 (27) 8/39 (21)
≥4 11/74 (15) 5/39 (13)
Menopausal status, n/N (%)
Premenopausal 4/67 (6) 6/35 (17) 0.07
Menopausal 0/67 (0) 1/35 (3)
Postmenopausal 63/67 (94) 28/35 (80)
Incontinence, n/N (%)
No 33/70 (47) 17/38 (45) 0.07
Stress 24/70 (34) 20/38 (53)
Urge 11/70 (16) 1/38 (3)
Mixed 2/70 (3) 0/38 (0)
Oestrogen use, n/N (%)
Yes 5/50 (10) 2/37 (5) 0.45
No 45/50 (90) 35/37 (95)
Preoperative POP-Q stage, %
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incontinence, vaginal pain, discharge, urinary incontinence
and no reduction in prolapse symptoms.
In the surgery group (Table 4), the mean operation
time was 64 min (95% CI 54–75), and the median esti-
mated blood loss was 100 ml (IQR 100–300 ml). The
median hospital stay was 2 days (IQR 2–3 days). There
were two complications recorded during surgery. In one
woman, during anterior and posterior colporrhaphy dif-
fuse bleeding occurred. This patient used vitamin K an-
tagonists chronically which were bridged with subcuta-
neous low molecular weight heparin. The total estimated
blood loss in this patient was 1,000 ml, but she recov-
ered without needing transfusion. Another woman had a
bleed directly after a sacrospinous fixation combined
with an anterior colporrhaphy. She received four units
of packed cells due to a bleeding near the sacrospinal
ligament, which was successfully treated conservatively
with vaginal tamponade. She developed a haematoma
and was re-admitted to hospital for 1 day. The
haematoma resolved spontaneously and was treated con-
servatively. Postoperative recovery was complicated by a
urinary tract infection in four patients, by urinary reten-
tion in eight patients, and by a bleed in one patient who
was re-admitted and re-operated upon 12 days after ini-
tial surgery because of an arterial bleed at the posterior
vaginal wall.
A second intervention was performed in 31% of pa-
tients (23/74) in the pessary group, and in 10% of patients
(4/39) in the surgery group (p = 0.01; Table 5. The addi-
tional interventions in the pessary group included POP
surgery in 21 patients (28%), urinary incontinence surgery
in 1 patient (1%) and physiotherapy in 1 patient (1%). The
additional interventions in the surgery group included a
pessary in 1 patient (3%), a pessary combined with phys-
iotherapy in 2 patients (5%), and surgery for recurrent
POP combined with physiotherapy in 1 patient (3%).
Table 2 Disease-specific quality of life domain scores in both groups
Baseline 12 months
Pessary group (N = 70) Surgery group (N = 33) p value Pessary group (N = 60) Surgery group (N = 26) p value
Urogenital Distress Inventorya
Overactive bladder 11.1 (0–44) 22.2 (0–58) 0.02 0.0 (0–33) 5.6 (0–56) 0.56
Incontinence 16.1 (0–44) 24.2 (0–73) 0.16 16.7 (0–35) 33.3 (0–50) 0.96
Obstructive micturition 0.0 (0–65) 16.7 (0–70) 0.02 0.0 (0–35) 0.0 (0–33) 0.39
Pain/discomfort 16.4 (0–63) 33.1 (0–70) <0.01 0.0 (0–33) 0.0 (0–33) 0.74
Prolapse 33.3 (0–98) 33.3 (0–86) 0.64 0.0 (0–33) 0.0 (0–0) <0.01
Recurrent bladder infections, n (%)
Never 29 (41) 12 (36) 0.16 24 (40) 12 (46) 0.42
Once 4 (6) 7 (21) 2 (3) 3 (12)
2 to 4 times 4 (6) 3 (9) 5 (8) 1 (4)
> 4 times 1 (1) 0 (0) 1 (2) 0 (0)
Defecatory Distress Inventorya
Constipation 0.0 (0–23) 0.0 (0–47) 0.09 0.0 (0–17) 0.0 (0–55) 0.69
Obstructive defecation 0.0 (0–20) 8.3 (0–57) 0.28 0.0 (0–18) 0.0 (0–33) 0.21
Pain/discomfort 0.0 (0–33) 0.0 (0–17) 0.85 0.0 (0–33) 0.0 (0–22) 0.25
Incontinence 0.0 (0–17) 0 (0–17) 0.58 0.0 (0–33) 0.0 (0–0) 0.20
Incontinence flatus 0.0 (0–67) 33.3 (0–67) 0.09 0.0 (0–33) 33.3 (0–67) 0.18
Incontinence Impact Questionnaireb
Physical 0.0 (0–48) 0.0 (0–50) 0.50 0.0 (0–33) 0.0 (0–13) 0.07
Mobility 11.1 (0–44) 16.7 (0–56) 0.26 0.0 (0–33) 0 (0–31) 0.71
Social 0.0 (0–22) 11.1 (0–44) <0.01 0.0 (0–11) 0.0 (0–9) 0.86
Shame 0.0 (0–32) 0.0 (0–33) 0.23 0.0 (0–22) 0.0 (0–17) 0.99
Emotional 5.5 (0–43) 11.1 (0–67) 0.24 0.0 (0–37) 0.0 (0–11) 0.31
Sexuality, n/N (%)
Sexual intercourse 42/64 (66) 25/32 (78) 0.21 35/53 (68) 21/27 (82) 0.21
The data presented are median scores (10th to 90th percentile) except as otherwise indicated
a 0 not bothersome, 100 most bothersome
b 0 best quality of life, 100 worst quality of life
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Discussion
Main findings
In this study, we found that treatment preference limits pa-
tients’ willingness to undergo randomization. At 12 months
the pessary group reported more symptoms in the prolapse
domain of the UDI (the primary outcome) than the surgery
group. Women in the pessary group were also more likely to
need an additional intervention, and 28% needed surgical in-
tervention in contrast to women in the surgery group of whom
5% needed reoperation. Younger patients, with a higher POP-
Q stage and more severe urinary symptoms that affected their
social life were more likely to choose POP surgery.
Strengths and limitations
To our knowledge this is the first attempt to compare pessary
and surgery as primary treatments for women with POP in a
randomized trial. However, we were able to randomize only
six women, since a large majority of the eligible women had a
strong preference for one or other of the treatment options.
Therefore, we decided to halt the trail and report the data as
a prospective cohort study. Previous studies investigating
women with POP have also shown strong patient preference
for one or the other of two interventions [10]. Lamers et al.
[10] found that the likelihood of preferring pessary treatment
over surgery increases with increasing patient age. They con-
cluded that surgery is preferred over pessary treatment as POP
stage increases and if POP symptoms are more bothersome
and affect general wellbeing, and that patients who are sexu-
ally active also tend to prefer surgery over conservative treat-
ment [10]. In our study population, patient preference played
an important role, to such a degree that randomization was
very difficult.
Since most participating women were not randomized,
selection bias was likely to have played a role. It is pos-
sible that doctors counselled women differently depending
on patient characteristics such as age, comorbidity, sexual
activity, POP stage and POP symptoms, and how they
affect the woman’s daily activities. Because the groups
were not allocated by randomization, the baseline charac-
teristics were significantly different. The heterogeneity be-
tween the treatment groups is a reflection of normal daily
practice. The pessary group in our study consisted of older
women, as in previous studies [10]. The POP-Q stages of
the pessary group were higher, in contrast to previous
studies, but complaints were more bothersome in the sur-
gery group, as has been found in previous studies [10].
Table 4 Data concerning the initial treatment in the surgery group
Value
Type of operation (N = 39), n (%)
ACR 15 (39)
LH 1 (3)
SSF + ACR 9 (23)
SSF + ACR + PCR 1 (3)
ACR + PCR 7 (18)
MF + ACR 1 (3)
MF + ACR + PCR 1 (3)
TVH + ACR + PCR 1 (3)
TVH + ACR 1 (3)
TVH 2 (5)
Operative time (min), mean (95% CI) 64 (54–75)
Estimated blood loss (ml), median (IQR) 100 (100–300)
Hospital stay (days), median (IQR) 2 (2–3)
Complications during surgery (N = 39), n (%) 2 (5)
Bleeding, n 2
Complications during admission (N = 39), n (%) 13 (33)
Urinary tract infection, n 4
Bladder retention, n 8
Bleeding (reoperation), n 1
ACR Anterior colporrhaphy, PCR Posterior colporrhaphy, LH
Laparoscopic hysteropexy, TVH Transvaginal hysterectomy, MF
Manchester-Fothergill procedure, SSF Sacrospinous fixation
Table 3 Data concerning the initial treatment in the pessary group
Value
Type of pessary (N = 74), n (%)
Falk 10 (14)
Ring 64 (87)
Pessary expulsion (N = 74), n (%) 10 (14)
Side effects (N = 74), n (%) 36 (49)
Vaginal discharge 15 (20)
Vaginal pain 10 (14)
Urinary incontinence 7 (9)
Erosion 3 (4)
Bleeding 1 (1)
Continuation rates (N = 74), n (%)
4 weeks 60 (81)
3 months 60 (81)
6 months 47 (64)
1 year 44 (60)
Reason for discontinuation (N = 30), n (%)
Pessary expulsion 7 (23)
Urinary incontinence 6 (20)
Vaginal pain 6 (20)
Vaginal discharge 5 (17)
No symptom reduction 5 (17)
Urinary retention 1 (3)
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The patients’ unwillingness to be randomized is an out-
come in itself, as it reflects the strong differences between
the two interventions with respect to invasiveness, risk profile
and impact. The fact that the two treatment options are very
different led to a strong preference for one or the other.
However, in the OPUS trial [19], the randomization group
and the patient-preference group did not show any differences
in baseline characteristics or results. This might suggest that a
RCT is not the only study design that can usefully add to the
present literature, and the results of this prospective trial pro-
vide valuable conclusions. Following the advice of several
epidemiologists, we did not perform separate analyses for
our randomized and nonrandomized groups since the former
was too small.
Interpretation
This prospective cohort study comparing pessary treatment
and surgery as primary treatments for POP generated some
important lessons. As a randomized clinical trial comparing
the two strategies turned out not to be feasible, our prospective
study results can be used to counsel women. A strategy of
pessary treatment followed by surgery if needed, or a strategy
with immediate surgery both seem to be effective options for
the treatment of POP in women.
Both groups reported very low scores for almost all do-
mains of the UDI, DDI and IIQ, which suggests that both
treatments are effective. The pessary group reported signifi-
cantly more symptoms in the prolapse domain of the UDI.
However, the median scores were still very low (0, 10th to
90th percentile 0–33, in the pessary group; 0, 10th to 90th
percentile 0–0, in the surgery group), which is probably clin-
ically irrelevant. Previous studies have also shown that pessa-
ries are effective in improving pelvic floor dysfunction [6–9].
Most studies have shown improvements in both bulge and
irritative bladder symptoms following pessary treatment
[10], but two studies have also shown de novo stress urinary
incontinence [9, 20]. Patient satisfaction rates with
medium-term pessary use are high (70–92%) [20, 21].
Two prospective cohort studies comparing pessary treat-
ment and surgery have shown similar improvements in
urinary and bowel symptoms, sexual function, and quality
of life at 12 months [11–14].
The continuation rate of pessary treatment after 12 months
was 60%, whereas 72% of the women in the pessary did not
have an indication for surgical intervention. This result is very
important since it illustrates that both treatments are very ef-
fective in treating urinary, defaecation and prolapse symp-
toms, since the domain scores for the UDI, DDI and IIQ after
12 months were very low, with a median score of 0.0 for most
domains. Prospective trials have shown continuation rates be-
tween 50% and 80% after 1 year and between 14% and 48%
after 5 years [10]. However, evidence concerning
reinterventions is lacking. Although no cost analysis was per-
formed, these results suggests that pessary treatment is more
cost effective, since less surgery was performed and the do-
main scores for the UDI, DDI and IIQ at 12 months were low
in both groups.
The patient population was only 113 patients despite the
long study period. As the study was non-funded, we were not
able to register all patients who declined to participate.
Therefore, we cannot provide reliable data about a denomina-
tor. We included patients until there were 40 patients in each
group. Since there were only six randomized patients, we
decided, following advice from several epidemiologists, not
to perform a separate analysis for the two groups, but to ana-
lyse both groups together and present the data as a prospective
cohort study instead of a RCTwith a prospective cohort along-
side. Nevertheless, the results of the study provide evidence
on continuation rates, additional interventions, quality of life
and patient preference. These outcomes will help individual-
ize counselling on treatment options to provide better guid-
ance to patients with symptomatic POP in the treatment deci-
sion process. Younger patients with a lower POP-Q prolapse
Table 5 Additional interventions
Intervention Group p value
Pessary (N = 74) Surgery (N = 39)
Physiotherapy, n 1 0
Pessary, n 0 1
Prolapse surgery, n 21 0
Incontinence surgery 1 0
Total, n (%) 23 (31) 4 (10) 0.01
Combined
Prolapse and incontinence surgery, n 0 0
Prolapse surgery and physiotherapy, n 0 1
Pessary and physiotherapy, n 0 2
Time to second intervention (months), median (IQR) 3.0 (1.0–7.0) 10.0 (3.0–11.8) 0.17
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stage but more urinary symptoms that affect their social life
are more likely to choose POP surgery. This agrees with the
results of previous studies. A review on the topic shows that
the probability of choosing pessary treatment over surgery
increases with increasing patient age in accordance with the
results of this study. Surgery was preferred over pessary
treatmen if POP symptoms are more bothersome and affect
the general wellbeing of the patient [10].
Conclusion
Women with POP stage II or higher treated with a pessary are
bothered more by prolapse symptoms and more often undergo
surgery in the first year of follow-up than patients who are
treated surgically. However, pessary treatment allowed sur-
gery to be avoided in 72% of women, although prolapse
symptoms were less severe in those who had undergone sur-
gery. These outcomes will help individualize counselling on
treatment options and allow better guidance to patients with
symptomatic POP in the treatment decision process.
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